DR-4004 is a 5-HT7 receptor antagonist that alleviates performance deficits induced by mCPP and those resulting from p-chloroamphetamine (PCA)-induced 5-HT system damage; it also reverses memory impairment caused by scopolamine and dizocilpine. DR-4004 shows potential for research in schizophrenia, cognitive deficits, and atypical antipsychotic agents.